The t(5;14)(q31 ;q32) translocation from B-lineage acute lymphocytic leukemia with eosinophilia has been cloned from two leukemia samples. In both cases, this translocation joined the IgH gene and the interleukin-3 (IL-3) gene. In one patient, excess IL-3 mRNA was produced by the leukemic cells. In the second patient, serum IL-3 levels were measured and shown to correlate with disease NUMBER OF chromosome translocations have been A associated with human leukemia and lymphoma. In many cases the study of these translocations has led to the discovery or characterization of proto-oncogenes, such as bcl-2, c-abl, and c-myc, that are located adjacent to the translocation.'** It is now widely understood that cancerassociated translocations disrupt nearby proto-oncogenes.
hybridized with an IL-3 cDNA probe extending to the Xho I site in exon 5, a 720 bp Sst I/Kpn I probe derived from intron 2 of the IL-3 gene, a 600 bp Nhe IIHpa I IL-5 cDNA probe, and a 500 bp Pst IINco I granulocyte-macrophage colony stimulating factor (GM-CSF) cDNA probe."-'* Primers were designed with BamHI sites for cloning. One primer hybridized to the Jh sequences from the IgH gene (Primer 144:5'-TAGGATCCGACGGTGACCAGGGT), and the other hybridized to the region of the TATA box in the IL-3 gene (Primer 161 : 5'-AACAGGATCCCGCCTTATATGTGCAG). Polymerase chain reaction (PCR) (95OC for 1 minute, 61OC for 30 seconds, and 72OC for 3 minutes) was done using 500 ng genomic DNA and 50 pmol of each primer in 100 pL containing 67 mmol/L Tris-HC1 pH 8. 8, 6 .7 mmol/L MgCI,, 10% dimethyl sulfoxide (DMSO), 170 pg/mL bovine serum albumin (BSA) (fraction V),
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activity. There was no evidence of excess granulocyte1 macrophage colony stimulating factor (GM-CSF) or IL-5 expression. Our data support the formulation that this subtype of leukemia may arise in part because of a chromosome translocation that activates the IL-3 gene, resulting in autocrine and paracrine growth effects. 0 1990 by The American Society of Hematology.
16.6 mmol/L ammonium sulfate, 1.5 mmol/L each dNTP and Taq polymerase (Perkin-Elmer, Norwalk, CT)."
Sequencing was done by chain termination in MI3
vector^.'^ As part of this study, we sequenced a subclone of a normal IL-3 promotor, covering 598 base pairs from a Sma I site at position -1240 (with respect to the proposed site of transcription initiation)
to an Nhe I site at position -642. The plasmid containing this region was a gift from Naoko Arai of the DNAX Research Institute. A genomic IL-3 fragment from Case 1 was cloned into the pXM expression vector."' Briefly, the HindIIIl Sal I fragment containing the IL-3 gene was subcloned from the previously described phage clone 4 into pUC18.' The 2.6 kb fragment extending from the Sma I site 61 bp upstream of the IL-3 transcription start to the Sma I site in the polylinker was cloned into the blunted Xho I site of pXM. The negative control construct was the pXM vector without insert. Plasmids were introduced into cos7 cells by electroporation, and supernatant was collected after 48 hours in culture.
TF1 bioassay. TF-I cells were passaged in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum, 2 mmol L-glutamine, and 1 ng/mL human GM-CSF." Samples and antibodies were diluted in this same medium lacking GM-CSF but containing penicillin and streptomycin. A 25 pL volume of serial dilutions of patient serum was added to wells in a flat bottom 96-well microtiter plate. Rat anti-cytokine monoclonal antibody in a volume of 25 pL was added to appropriate wells and preincubated for 1 hour at 37OC. Fifty microliters of twice washed TF-1 cells were added to each well, giving a final cell concentration of 1 x IO4 cells per well (final volume, 100 pL). The plate was incubated for 48 hours. The remaining cell viability was determined metabolically by the colori-
Sequencing.
Expression in Cos7 cells. These assays used rat monoclonal anti-cytokine antibodies (10 pg/mL) to coat the wells of a PVC microtiter plate. The capture antibodies used were BVD3-6G8, JESl-39Dl0, and BVD2-23B6, for the IL-3, IL-5, and GM-CSF assays, respectively. Patient sera were then added (undiluted and diluted 1:2 for IL-3, undiluted for IL-5, and undiluted and diluted 1:5 for GM-CSF). The detecting immunoreagents used were either mouse antiserum to IL-3 or nitroiodophenyl (NIP)-derivatized rat monoclonal antibodies JESl-5A2 and BVD2-21Cl1, specific for IL-5 and GM-CSF, respectively. Bound antibody was subsequently detected with immunoperoxidase conjugates: horseradish peroxidase (HRP)-labeled goat anti-mouse Ig for IL-3, or HRP-labeled rat (54 MoAb) anti-NIP for IL-5 and GM-CSF. The chromogenic substrate was 3-3'azino-bis-benzthiazoline sulfonate (ABTS; Sigma, St Louis, MO). Unknown values were interpolated from standard curves prepared from dilutions of the recombinant factors using Softmax software available with the VMAX microplate reader (Molecular Devices).
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RESULTS
Leukemic DNA from Case 2 was studied by Southern blotting. When digested with the Hind111 restriction enzyme and hybridized with a human immunoglobulin heavy chain joining region (Jh) probe, a rearranged fragment at approximately 14 kb was detected (data not shown). When reprobed with either of two different IL-3 probes, .a rearranged 14 kb #a #l fragment, comigrating with the rearranged Jh fragment, was identified. When leukemic DNA was digested with Hind111 plus EcoRI, a rearranged Jh fragment was detected at 6 kb. The IL-3 probes also identified a comigrating fragment of this size. These experiments indicated that the leukemic sample studied was clonal and that a single fragment contained both Jh and IL-3 sequences, suggesting a translocation had occurred.
To characterize better the joining of the IL-3 gene and the immunoglobulin heavy chain (IgH) gene, the polymerase chain reaction (PCR) was used to clone the translocation.'3 A Jh primer and an IL-3 primer were designed to produce an amplified product in the event of a head-to-head translocation. While control DNA gave no PCR product, Case 2 DNA yielded a PCR-derived fragment of approximately 980 bp, which was cloned and sequenced.
The DNA sequence of the translocation clone from Case 2 confirmed the joining of the Jh region with the promotor of the IL-3 gene in a head-to-head configuration (Fig 1) . Sequence analysis indicated that the breakpoint on chromosome 14 was just upstream of the Jh5 coding region. The breakpoint on chromosome 5 occurred 934 bp upstream of the putative site of transcription initiation of the IL-3 gene. We also determined that a putative N sequence of 17 bp was inserted between the chromosome 5 and chromosome 14 sequences during the translocation event.".'* Figure the locations of the two cloned breakpoints in relation to the IL-3 gene. The two chromosome 5 breakpoints were separated by less than 500 bp.
The genomic structure in Cases 1 and 2 suggested that a normal IL-3 gene product was over-expressed as a result of the altered promotor structure. This would predict that the IL-3 gene on the translocated chromosome was capable of making IL-3 protein. This prediction was tested by expressing a genomic fragment from the translocated allele of Case 1 containing all five IL-3 exons under the control of the SV40 promotor/enhancer in the cos7 cell line. Cell supernatants were studied in a proliferation assay using the factor dependent erythroleukemic cell line, TF-I. The supernatants derived from transfections using the vector plus insert supported TF-1 proliferation, while supernatants from transfections using the vector alone were negative in this assay (data not shown). Furthermore, the biologic activity could be blocked by an antibody to human IL-3 (BVD3-6G8). This result showed that the translocated allele retained the ability to make IL-3 mRNA and protein.
The level of expression of IL-3 mRNA in leukemic cells from Case 1 was assessed. Northern blotting showed that the mature IL-3 mRNA (approximately 1 kb) and a 2.9 kb unspliced IL-3 mRNA were excessively produced by the leukemia (Fig 3) . The 2.9 kb form of the mRNA is also present at low levels in normal peripheral blood T lymphocytes after mitogen activation (Fig 3) . Several B-lineage acute leukemia samples without the t(5;14) translocation had undetectable levels of IL-3 mRNA in these experiments. In addition, although genes for GM-CSF and IL-5 map close to the IL-3 gene and might have been deregulated by the translocation, no IL-5 or GM-CSF mRNA could be detected in the leukemic sample (data not ~hown).'~.~' Three serum samples from Case 2 were assayed by immunoassay for levels of IL-3, GM-CSF, and IL-5 ( Table  I) . Serum IL-3 could be detected and correlated with the clinical course. When the patient's leukemic cell burden was highest, the IL-3 level was highest. No serum GM-CSF or IL-5 could be detected.
Since the IL-3 immunoassay measured only immunoreactive factor, we confimed that biologically active IL-3 was present by using the TF-1 bioassay. This bioassay can be rendered monospecific using appropriate neutralizing monoclonal antibodies specific for IL-3, IL-5, or GM-CSF. We observed that sera from 1-16-84 and 3-14-84 contained TF-1 stimulating activity that could be blocked with anti-IL-3 MoAb (BVD3-6G8). but not with MoAbs to IL-5 (JESl-39D10) or GM-CSF (BVD2-23B6) (Fig 4; GM-CSF data not shown). The amount of neutralizable bioactivity in these two samples correlated very well with the difference in IL-3 levels obtained by immunoassay for these samples. Furthermore, the failure to block TF-1 proliferating activity with either anti-IL-5 or anti-GM-CSF was consistent with the inability to measure these factors by immunoassay and indicated that these other myeloid growth factors were not detectably circulating in the serum of this patient.
DISCUSSION
In this report, we have extended our analysis of acute lymphocytic leukemia and eosinophilia associated with the t(5;14) translocation. In both cases we have studied, we have documented the joining of the IL-3 gene from chromosome 5 to the IgH gene from chromosome 14. The breakpoints on chromosome 5 are within 500 bp of each other, suggesting that additional breakpoints will be clustered in a small region of the IL-3 promotor. The PCR assay we have developed will be useful in the screening of additional clinical samples for this abnormality.
The finding of a disrupted IL-3 promotor associated with an otherwise normal IL-3 gene implied that this translocation might lead to the over-expression of a normal IL-3 gene product. In this work, we have documented that this is true. In addition, neither GM-CSF nor IL-5 are over-expressed by the leukemic cells. Furthermore, in one patient, serum IL-3 could be measured and correlated with disease activity. To our knowledge, this is the first measurement of human IL-3 in serum and its association with a disease process. The measurement of serum IL-3 in this and other clinical settings may now be indicated.
The finding of the IL-3 gene adjacent to a cancerassociated translocation breakpoint suggests that its activation is important for oncogenesis. It is our thesis that an autocrine loop for IL-3 is important for the evolution of this leukemia.2' The excessive IL-3 production that we have documented would be one feature of such an autocrine loop. The final proof of our thesis must await additional data. In particular, from the study of additional clinical samples, it will be necessary to document that the IL-3 receptor is present on the leukemic cells and that anti-IL-3 antibody decreases proliferation of the leukemia in vitro.
An important aspect of this work is the suggestion of a therapeutic approach for this disease. If an autocrine loop for IL-3 can be documented in this disease, attempts to lower circulating IL-3 levels or block the interaction of IL-3 with its receptor may prove useful. Because it is also possible that the eosinophilia in these patients is mediated by the paracrine effects of leukemia-derived IL-3, similar interventions may improve this aspect of the disease. Antibodies or engineered ligands to accomplish these goals may soon be available.
